Sequential or Alternating Doxorubicin and CMF Regimens in Breast Cancer With More Than Three Positive Nodes: Ten-Year Results

JAMA: The Journal of the American Medical Association

Volumn 273, Issue 7, 1995, Pages 542-547

  Bonadonna, Gianni ^a   Zambetti, Milvia ^a   Valagussa, Pinuccia ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL;

EID: 0028813358     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1995.03520310040027     Document Type: Article

References (24)

1. Fisher B. The evolution of paradigms for the management of breast cancer: a personal perspective. Cancer Res. 1992;52:2371-2383.
2. Bonadonna G. Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res. 1992;52:2127-2137.
3. Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 1976;294:405-410.
4. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) in node positive breast cancer: twenty years later. N Engl J Med. In press.
5. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet. 1992; 399:1-15, 71-85.
6. Tancini G, Bonadonna G, Valagussa P, Marchini S, Veronesi U. Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. J Clin Oncol. 1983;1:2-10.
7. Moliterni A, Bonadonna G, Valagussa P, Ferrari L, Zambetti M. Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes. J Clin Oncol. 1991;9:1124-1130.
8. Buzzoni R, Bonadonna G, Valagussa P, Zambetti M. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J Clin Oncol. 1991;9:2134-2140.
9. Veronesi U, Banfi A, Salvadori B, et al. Breast conservation is the treatment of choice in small breast cancer: long-term results of a randomized trial. Eur J Cancer. 1990;26:668-670.
10. Bonadonna G, Valagussa P. Dose response effect of adjuvant chemotherapy in breast cancer. N Engl J Med. 1981;304:10-15.
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
12. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc [A]. 1972; 135:185-206.
13. Cox DR. Regression models and life tables (with discussion). J R Stat Soc [B]. 1972;34:187-220.
14. Miller RC. Survival Analysis. New York, NY: John Wiley & Sons; 1981.
15. Bonadonna G, Valagussa P, Rossi A, et al. Tenyear experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat. 1985;5:95-115.
16. Bonadonna G, Beretta G, Tancini G, et al. Adriamycin studies at the Istituto Nazionale Tumori, Milan. Cancer Chemother Rep. 1975;6:231-245.
17. Bonfante V, Ferrari L, Brambilla C, et al. New anthracycline analogs in advanced breast cancer. Eur J Cancer Clin Oncol. 1986;22:1379-1385.
18. Harris JR, Hellman S, Henderson IC, eds. Breast Diseases. 2nd ed. Philadelphia, Pa: JB Lippincott; 1991.
19. Valagussa P, Zambetti M, Bonadonna G, Zucali R, Mezzanotte G, Veronesi U. Prognostic factors in locally advanced noninflammatory breast cancer: long-term results following primary chemotherapy. Breast Cancer Res Treat. 1990;15:137-147.
20. Bonadonna G, Valagussa P, Santoro A. Alternating non—cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease: a report of 8-year results. Ann Intern Med. 1986; 104:739-746.
21. Valagussa P, Zambetti M, Biasi S, Moliterni A, Zucali R, Bonadonna G. Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer. Ann Oncol. 1994;5:209-216.
22. Valagussa P, Moliterni A, Terenziani M, Zambetti M, Bonadonna G. Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer. Ann Oncol. 1994;5:803-808.
23. Henderson IC. Adjuvant systemic therapy for early breast cancer. Cancer. 1994;74:401-409.
24. Wood WC, Budman DR, Korzun AH, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med. 1994;330:1253-1259.